BH3 mimetics: Status of the field and new developments

Molecular Cancer Therapeutics

Volumn 12, Issue 9, 2013, Pages 1691-1700

  Billard, Christian ^a  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABT 199; ANTINEOPLASTIC AGENT; APOGOSSYPOL; APOGOSSYPOLONE; BAM 7; BH3 M6; BH3 MIMETIC; BH3 PROTEIN; BI 97C1; BI97 D6; BIM SAHB; CHELERYTHRINE; GOSSYPOL; GOSSYPOL DERIVATIVE; HETEROCYCLIC COMPOUND; ISOSORBIDE; MARITOCLAX; MCL 1 INHIBITOR MOLECULE 1; NAVITOCLAX; OBATOCLAX; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; QUINOLINE DERIVATIVE; S1; S1 DERIVATIVE; SABUTOCLAX; TERPHENYL DERIVATIVE; TW 37; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; BIOMIMETICS; CANCER THERAPY; CELL DEATH; CHEMICAL STRUCTURE; CHRONIC LYMPHATIC LEUKEMIA; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ISOLATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENANTIOMER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LEUKEMIA CELL; MOLECULAR INTERACTION; MOLECULARLY TARGETED THERAPY; NEOPLASM; NEUROTOXICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN MOTIF; REVIEW; STREPTOMYCES; TREATMENT OUTCOME; TUMOR MODEL; X RAY CRYSTALLOGRAPHY;

AMINO ACID MOTIFS; ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BICYCLO COMPOUNDS, HETEROCYCLIC; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; GOSSYPOL; HUMANS; MOLECULAR MIMICRY; NEOPLASMS; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES; SULFONAMIDES;

EID: 84884520490     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0058     Document Type: Review

References (66)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
2. Reed JC. Apoptosis-targeted therapies for cancer. Cancer Cell 2003;3:17-22.
3. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nature Rev 2010;9:447-64.
4. Reed JC, Pellecchia M. Apoptosis-based therapies for hematologic malignancies. Blood 2005;106:408-18.
5. Lessene G, Czabotar PE, Colman PM. Bcl-2 family antagonists for cancer therapy. Nature Rev 2008;7:989-1000.
6. Strasser A, Cory S, Adams JM. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J 2011;30:3667-83.
7. Baell JB, Huang DCS. Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. Biochem Pharmacol 2002;64:851-63.
8. Azmi AA, Wang Z, Philip PA, Mohammad RM, Sarkar FH. Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opin Emerging Drugs 2011;16:59-70.
9. Khaw SL, Huang DCS, Roberts AW. Overcoming blocks in apoptosis with BH3-mimetic therapy in hematological malignancies. Pathology 2011;43:525-35.
10. Shamas-Din A, Brambhatt H, Leber B, Andrews DW. BH3-only proteins: orchestrators of apoptosis. Biochim Biophys Acta 2011;18: 508-20.
11. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumors. Nature 2005;435:677-81.
12. Tse C, Shoemaker AR, Adickers J, Chen J, Jin S, Johnson EF, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-8.
13. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006;10:389-99.
14. Vogler M, Weber K, Dinsdale D, Schmitz I, Schultze-Hosthoff K, Dyer MJS, et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Diff 2009;16:1030-9.
15. Albershardt TC, Salerni BL, Soderquist RS, Bates DJP, Pletnev AA, Kisselev AF, et al. Multiple BH3 mimetics antagonize antiapoptotic MCL-1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA. J Biol Chem 2011; 286:24882-95.
16. Billard C. Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia. Leukemia 2012;26:2032-8.
17. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alterations across human cancers. Nature 2010;463:899-905.
18. Quinn BA, Dash R, Azab B, Sarkar S, Das SK, Kumar S, et al. Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs 2011;20:1397-411.
19. Billard C. Development of Noxa-like BH3 mimetics for apoptosisbased therapeutic strategy in chronic lymphocytic leukemia. Mol Cancer Res 2012;10:673-6.
20. Kazi A, Sun J, Doi K, Sung SS, Takahashi Y, Yin H, et al. The BH3 a-helical mimic BH3-M6 disrupts Bcl-XL, Bcl-2, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner. J Biol Chem 2011;286:9382-92.
21. Delgado-Soler L, Pinto M, Tanaka-Gil K, Rubio-Martinez J. Molecular determinants of Bim(BH3) peptide binding to pro-survival proteins. J Chem Inf Model 2012;52:2107-18.
22. LaBelle JL, Katz SG, Bird GH, Gavathiotis E, Stewart ML, Lawrence C, et al. A stapled Bim peptide overcomes apoptotic resistance in hematologic cancers. J Clin Invest 2012;122:2018-31.
23. Maiuri MC, Criollo A, Tasdemir E, Vicencio JM, Tajeddine N, Hickman JA, et al. BH3-only proteins and BH3 mimetics induce autopaghy by competitively disrupting the interaction between Beclin 1 and Bcl-2/ Bcl-X(L). Autophagy 2007;3:374-6.
24. Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, et al. Navitoclax, a targeted high-affinity inhibitor of Bcl-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumor activity. Lancet Oncol 2010;11:1149-59.
25. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, et al. Phase 1 study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patientswith small-cell lung and other solid tumors. J Clin Oncol 2011;29:909-16.
26. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Carney DA, et al. Substancial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012;30:488-96.
27. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Madiraju SRM, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Pro Natl Acad Sci USA 2007;104:19512-7.
28. Joudeh J, Claxton D. Obatoclax mesylate: pharmacology and potential for therapy of hematological neoplasms. Expert Opin Investig Drugs 2012;21:363-73.
29. Kitada S, Leone M, Sareth S, Zhai D, Reed JC, Pellecchia M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem 2003;46:4259-64.
30. Arnold AA, Aboukamel A, Chen J, Yang D, Wang S, Al-Katib A, et al. Preclinical studies of apogossypolone: a new nonpeptidic pan smallmolecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in follicular small cleaved cell lymphoma model. Mol Cancer 2008;7:20.
31. Wei J, Stebbins JL, Kitada S, Sash R, Zhai D, Placzek WJ, et al. An optically pure apogossypolone derivative as potent pan-active inhibitor of anti-apoptotic Bcl-2 family proteins. Front Oncol 2011;1:28.
32. Wei J, Stebbins JL, Kitada S, Dash R, Placzek W, Rega M, et al. BI- 97C1, an optically pure apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem 2010;53:4166-76.
33. Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright RD, et al. Activation of apoptosis in vivo by an hydrocarbon-stapled BH3 helix. Science 2004;305:1466-70.
34. Zhang Z, Song T, Zhang T, Gao J, Wu G, An L, et al. A novel BH3 mimetic S1 potently induces Bax/Bak-dependent apoptosis by targeting both Bcl-2 and Mcl-1. Int J Cancer 2011;128:1724-35.
35. Ghiotto F, Fais F, Tenca C, Tomati V, Morabito F, Casciaro S, et al. Apoptosis of B-cell chronic lymphocytic leukemia cells induced by a novel BH3 peptidomimetic. Cancer Biol Ther 2009;8:263-71.
36. Lee EF, Czabotar PE, van Delft MF, Michalak EM, Boyle MJ, Willis SN, et al. A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation. J Cell Biol 2008;180:341-55.
37. Stewart ML, Fire E, Keating AE, Walensky LD. The MCL-1 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat Chem Biol 2010;6:595-601.
38. Gavathiotis E, Suzuki M, Davis ML, Pitter K, Bird GH, Katz SG, et al. BAX activation is initiated at a novel interaction site. Nature 2008;455:1076-82.
39. Gavathiotis E, Reyna DE, Davis ML, Bird GH, Walensky LD. BH3- triggered structural reorganization drives the interaction of proapoptotic BAX. Mol Cell 2010;40:481-92.
40. Song T, Chang X, Zhang Z, Liu Y, Shen X. S1, a novel pan-BH3 mimetic, induces apoptosis in Mcl-1-overexpressing cells through Bak. J Pharmacol Sci 2012;119:330-40.
41. Zhong JT, Xu Y, Yi HW, Su J, Yu HM, Xiang XY, et al. The BH3 mimetic S1 induces autophagy through ER stress and disruption of Bcl-2/ Beclin 1 interaction in human glioma U251 cells. Cancer Lett 2012; 323:180-7.
42. Balakrishnan K, Aggarwal S, Wierda W, Gandhi V. Bax and Bak are required for apogossypolone, a BH3 mimetic, induced apoptosis in chronic lymphocytic leukemia. Leuk Lymphoma 2012;54:1097-100.
43. Espona-Fiedler M, Soto-Cerrato V, Hosseini A, Lizcano JM, Guallar V, Quesada R, et al. Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: prodigiosin vs. obatoclax. Biochem Pharmacol 2012;83:489-96.
44. Smoot RL, Blechacz BRA, Werneburg NW, Bronk SF, Sinicrope FA, Sirica AE, et al. A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells. Cancer Res 2010;70:1960-9.
45. Song T, Li X, Chang X, Liang X, Zhao Y,WuG, et al. 3-thiomorpholin-8- oxo-8H-acenaphto [1,2-b] pyrrole-9-carbonitrile (S1) derivatives as pan-Bcl-2-inhibitors of Bcl-2, Bcl-xL and Mcl-1. Bioorg Med Chem 2013;21:11-20
46. Saugues E, Debaud AL, Anizon F, Bonnefoy N, Moreau P. Synthesis and biological activities of polyquinoline derivatives: new Bcl-2 family protein modulators. Eur J Med Chem 2012;57:112-25.
47. Hugues CC, Prieto-Davo A, Jensen PR, Fenical W. The marinopyrroles, antibiotics of an unprecendented structure class from a marine Streptomyces sp. Org Lett 2008;10:629-31.
48. Doi K, Li R, Sung SS, Wu H, Liu Y, Manieri W, et al. Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J Biol Chem 2012;287:10224-35.
49. Wong C, Anderson DJ, Lee EF, Fairlie WD, Ludlam MJC. Direct visualization of Bcl-2 family protein interactions using live cell fluorescent protein redistribution assays. Cell Death Dis 2012;3:e288.
50. Pinto M, Orzaez Mdel M, Delgado-Soler L, Perez JJ, Rubio-Martinez J. Rational design of new class of BH3-mimetics as inhibitors of the BclxL protein. J Chem Inf Model 2011;51:1249-58.
51. Brady RM, Hatzis E, Connor T, Street IP, Baell JB, Lessene G. Synthesis of conformationally constrained benzoylureas as BH3- mimetics. Org Biomol Chem 2012;10:5230-7.
52. Boersma MD, Haase HS, Peterson-Kaufman KJ, Lee EF, Clarke OB, Colman PM, et al. Evaluation of diverse a-b-backbone patterns for functional a-helix mimicry: analogues of the Bim BH3 domain. J Am Chem Soc 2012;134:315-23.
53. Joseph TL, Lane DP, Verma CS. Stapled BH3 peptides against Mcl-1: mechanism and design using atomistic simulations. PLoS ONE 2012; 7:e43985.
54. Boersma MD, Sadowsky JD, Tomita YA, Gellman SH. Hydrophile scanning as a complement to alanine scanning for exploring and manipulating protein-protein recognition: application to the Bim BH3 domain. Protein Sci 2008;17:1232-40.
55. Bernardo P H, Sivaraman TS, Wan KF, Xu J, Krishnamoorthy J, Song CM, et al. Structural insights into the design of small molecule inhibitors that selectively antagonize Mcl-1. J Med Chem 2010; 53:2314-8.
56. Dutta S, Gulla S, Chen TS, Fire E, Grant RA, Keating AE. Determinants of BH3 binding specificity for Mcl-1 versus Bcl-xL. J Mol Biol 2010;398:747-62.
57. Placzek WJ, Sturlese M, Wu B, Cellitti JF, Wei J, Pellecchia M. Identification of a novel Mcl-1 Protein binding motif. J Biol Chem 2011;286:39829-35.
58. Friberg A, Vigil D, Zhao B, Daniels RN, Burke JP, Garcia-BarrantesPM, et al. Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. J Med Chem 2012;56:15-30.
59. Bajwa N, Chenzong L, Nikolovska-Coleska Z. Inhibitors of the antiapoptotic Bcl-2 proteins: a patent review. Expert Opin Ther Patents 2012;22:37-55.
60. Muppidi A, Doi K, Edwardraja S, Drake EJ, Gulick AM, Wang HG, et al. Rational design of proteolytically stable, cell-permeable peptidebased selective Mcl-1 inhibitors. J Am Chem Soc 2012;134:14734-7.
61. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013;19:202-8.
62. Davids MS, Letai A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol 2012;30:3127-35.
63. Davids MS, Roberts AW, Anderson MA, Pagel JM, Kahl BS, Gerecitano JF, et al. The BCL-2-specific-mimetic ABT-199 (GDC-0199) is active and well-tolerated in patients with relapsed non-Hodgkin lymphoma: interim results of a phase I study [abstract]. In: Proceedings of the 54th ASH Annual Meeting and Exposition; 2012 Dec 8-11; Atlanta, GA. Washington, DC: ASH; 2012. Abstract nr 304.
64. Cohen NA, Stewart ML, Gavathiotis E, Tepper JL, Bruekner SL, Koss B, et al. A competitive stapled peptide screen identifies a selective small molecule that overcomes Mcl-1-dependent leukemia cell survival. Chem Biol 2012;19:1175-86.
65. Kritzer JA. The secret of MIM: a novel, Mcl-1-specific small molecule. Chem Biol 2012;19:1082-3.
66. Gavathiotis E, Reyna DE, Bellairs JA, Leshchiner ES, Walensky LD. Direct and selective small-molecule activation of proapoptotic BAX. Nat Chem Biol 2012;8:639-45.